Nature biomedical engineeringHumansT-LymphocytesReceptorsChimeric AntigenImmunotherapy
Fine tuning towards the next generation of engineered T cells.
Tham T Nguyen, Patrick Ho, Sarah Staudt, Celine Gregoire, Kai Ziegler-Martin, Megane Jassin, Alix Block, Michael Hudecek, J Joseph Melenhorst, Jo Caers, Maik Luu
Published: 202510.1038/s41551-025-01492-8
Abstract
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in treating haematologic malignancies. However, the rise in clinical use has highlighted substantial challenges related to T cell- and tumour-intrinsic mechanisms. Additio…
Preview only. Read the full abstract at the source